Breaking News

Tweet TWEET

Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases

      Sun Pharma and Intrexon Form Joint Venture to Develop New Class of
                       Therapeutics for Ocular Diseases

Pipeline of Potential Ocular Therapies to Help Millions Worldwide Suffering
from Blinding Diseases

PR Newswire

MUMBAI, India, and GERMANTOWN, USA, Oct. 1, 2013

MUMBAI, India, and GERMANTOWN, USA, Oct. 1, 2013 /PRNewswire/ --Sun
Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:
SUNPHARMA, BSE: 524715), an international specialty pharmaceutical company
focused on chronic diseases, through its subsidiary, and Intrexon Corporation
(NYSE: XON), a leader in synthetic biology, today announced the formation of a
joint venture to develop controllable gene-based therapies for the treatment
of ocular diseases that cause partial or total blindness in millions of people
worldwide. Initial targets are dry age-related macular degeneration (AMD),
glaucoma and retinitis pigmentosa.

The joint venture will leverage Sun Pharma's global capabilities and
experience in developing and manufacturing complex dosage forms and specialty
pharmaceuticals for niche therapy areas. Intrexon and Sun Pharma will share in
both the financing of, and the revenues from, the joint venture.

Through an Exclusive Channel Collaboration (ECC), the joint venture will have
access to Intrexon's full suite of proprietary synthetic biology technologies,
including the RheoSwitch Therapeutic System^® (RTS^®) platform. RTS^® is a
clinically validated method for controlling the location, concentration and
timing of protein expression. RTS^® may address a long-standing limitation of
current approaches by enabling patients to receive a targeted biologic therapy
without having to endure a lifetime of injections.

In addition to the initial targets, the companies intend to further expand the
future pipeline of targeted ocular diseases to potentially include wet AMD,
macular edema, non-infectious uveitis and diabetic retinopathy.

Samuel Broder, M.D., Senior Vice President of Intrexon's Health Sector and
former Director of the National Cancer Institute, noted that current
treatments for major ocular disorders require frequent and often painful
interventions that, at best, only slow the progression of the disease.

"Using our RTS^® platform, the goal is to engineer a gene-based ocular
treatment in which the concentration, location and timing of protein
expression can be controlled with small molecule therapy," Dr. Broder said.
"In combination with Sun Pharma's tremendous development and manufacturing
experience, we hope to produce a therapy that is minimally invasive as well as
maximally effective in treating these debilitating diseases."

Dilip Shanghvi, Managing Director of Sun Pharma, said "We believe Intrexon's
biotechnology capabilities will enable us to develop not one, but several
highly effective, novel treatments for multiple ocular disorders where there
is currently an unmet need. Through this partnership it is our goal to
provide relief for millions of people who today have very few treatment
options and little hope of preserving their vision."

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, said the
collaboration between Sun Pharma and Intrexon is a model relationship aligned
to accelerate development and production of new bio-engineered therapies.

"Today, more people suffer from ocular diseases than cancer," Kirk said. "To
address this immense unmet need, our innovative collaboration will unite Sun
Pharma's global capability to develop and manufacture complex pharmaceuticals
with Intrexon's proprietary cell and gene engineering technologies. We share
Sun Pharma's enthusiasm for the potential of our venture to produce a pipeline
of product opportunities aimed at well-validated therapeutic targets."

About Sun Pharma
Established in 1983, listed since 1994 and headquartered in India, Sun Pharma
(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an
international, integrated, specialty pharmaceutical company. It manufactures
and markets a large basket of pharmaceutical formulations as branded generics
as well as generics in India, US and several other markets across the world.
In India, the company is a leader in niche therapy areas of psychiatry,
neurology, cardiology, nephrology, gastroenterology, orthopedics and
ophthalmology. The company has strong skills in product development, process
chemistry, and manufacturing of complex API, as well as dosage forms. More
information about the company can be found at www.sunpharma.com.

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on
collaborating with companies in Health, Food, Energy and the Environment to
create biologically-based products that improve the quality of life and the
health of the planet. Through the company's proprietary UltraVector^®
platform, Intrexon provides its partners with industrial-scale design and
development of complex biological systems. The UltraVector^® platform
delivers unprecedented control over the quality, function, and performance of
living cells. We call our synthetic biology approach and integrated
technologies Better DNA®, and we invite you to discover more at www.dna.com.

Trademarks
Intrexon, RheoSwitch Therapeutic System, UltraVector and Better DNA are
trademarks of Intrexon and/or its affiliates. Other names may be trademarks
of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking
statements. These forward-looking statements are based upon our current
expectations and projections about future events and generally relate to our
plans, objectives and expectations for the development of our business.
Although management believes that the plans and objectives reflected in or
suggested by these forward-looking statements are reasonable, all
forward-looking statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release.

For more information contact:

Sun Pharma Contacts:

Nimish Desai                           Mira Desai
Tel        +91 22 6645 5645, Xtn 717   Tel        +91 22 6645 5645, Xtn 606
Tel Direct +91 22 6645 5717            Tel Direct +91 22 66455606
Mobile     +91-98203 30182             Mobile     +91 98219 23797
E mail     nimish.desai@sunpharma.com  E mail     mira.desai@sunpharma.com


Intrexon Corporation Contacts:

Peter McLaughlin                        Marie L. Rossi, Ph.D.

Vice President, Corporate               Manager, Technical Communications
Communications
Tel      +1 (323) 842-7779              Tel               +1 (301) 556-9944
E mail   pmclaughlin@intrexon.com       E mail            mrossi@intrexon.com


SOURCE Intrexon Corporation

Website: http://www.dna.com